GlucoseWire

Signal over noise for diabetes tech and care news.

Daily diabetes tech signal

Three meaningful updates. Practical context. No endless scrolling.

GlucoseWire curates important developments in diabetes technology, research, access, and care news so readers can quickly understand what changed and why people may care.

Today’s Signal

What Matters Now

Updated daily

Access

Dexcom expects broader Medicare CGM access for type 2 users

Read source: Investor's Business Daily ↗

What this means: Continuous glucose monitoring may become accessible to many more people with type 2 diabetes over the next several years.

Affordability

California launching lower-cost state-branded insulin

Read source: San Francisco Chronicle ↗

What this means: States and public programs are increasingly exploring direct ways to improve insulin affordability and access.

Research

AI-based CGM prediction tools continue improving

Read source: arXiv ↗

What this means: Diabetes technology continues moving toward more personalized prediction and decision-support tools.

About

Focused updates, not medical advice.

GlucoseWire curates important developments in diabetes technology, research, access, and care news to help readers quickly understand what changed and why people may care.

The goal is to reduce noise and surface meaningful updates around devices, automated insulin delivery, glucose monitoring, access, and emerging trends.

GlucoseWire is an editorial and informational project. It does not provide medical advice, treatment recommendations, or clinical guidance.

Coming Soon

Live feed

A cleaner stream of curated device, research, and access updates.

Podcast tracking

Highlights from diabetes podcasts and other high-signal sources.

Device filtering

Follow developments by company, device, category, or topic.